HealthcareServices

Revenue of the Liraglutide And Semaglutide Market Predicted to Achieve $28.98 Billion by 2030, Driven by 11.3% CAGR

February 26, 2026February 26, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the liraglutide and semaglutide market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Liraglutide And Semaglutide Market?

The liraglutide and semaglutide market size has seen rapid growth recently. This market is forecast to expand from $16.94 billion in 2025 to $18.88 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.5%. Historically, the market’s growth can be linked to factors such as the increasing prevalence of type 2 diabetes mellitus, the limitations of traditional antidiabetic therapies, growing obesity rates, the clinical success of injectable glp-1 drugs, and rising awareness of cardiovascular risk reduction.

The market for liraglutide and semaglutide is projected to experience swift expansion over the coming years. This market is anticipated to reach a valuation of $28.98 billion by 2030, growing at a compound annual growth rate (CAGR) of 11.3%. Factors contributing to this growth during the forecast period include broader indications for obesity treatment, an increasing need for user-friendly dosing choices, the rising uptake of oral semaglutide, an intensified emphasis on holistic metabolic health, and elevated healthcare expenditure on managing chronic diseases. Key trends expected during this period involve the greater acceptance of GLP-1 receptor agonists for diabetes management, increased application of GLP-1 therapies in weight management, a growing inclination towards once-weekly injectable medications, the proliferation of oral GLP-1 formulations, and a rise in long-term utilization for blood sugar and weight regulation.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18400&type=smp

What Drivers Are Supporting Technological Adoption In The Liraglutide And Semaglutide Market?

An increasing population of individuals with diabetes is anticipated to fuel the expansion of the liraglutide and semaglutide markets in the future. Diabetes is a persistent medical state marked by heightened blood glucose levels, stemming from the body’s resistance to insulin and inadequate insulin synthesis. The growing incidence of diabetic individuals is linked to inactive lifestyles, unhealthy eating patterns, and hereditary factors. Liraglutide and semaglutide play a crucial role in the treatment of diabetic patients, providing efficient control over blood glucose and mitigating the likelihood of diabetes-related complications. As an illustration, data from June 2024 released by the National Health Service, a UK government body, indicated that in 2023, the NHS identified more than 549,000 new individuals in England facing the risk of developing type 2 diabetes. This raised the overall count of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a general practitioner to 3,615,330. This figure signifies a considerable jump from the 3,065,825 recorded in 2022, reflecting an increase of almost 20%. Consequently, the increasing prevalence of diabetic patients serves as a key driver for the liraglutide and semaglutide markets.

Which Segments Are Contributing To The Growth Of The Liraglutide And Semaglutide Market?

The liraglutide and semaglutide market covered in this report is segmented –

1) By Type: Pills, Liquid

2) By Administration: Parenteral, Oral

3) By Application: Type 2 Diabetes Mellitus, Obesity, Other Applications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Pills: Oral Tablets (Liraglutide, Semaglutide), Extended-Release Oral Formulations

2) By Liquid: Injectable Solutions (Liraglutide, Semaglutide), Pre-Filled Syringes, Vials For Injection

What Trends Are Expected To Impact The Competitive Landscape Of The Liraglutide And Semaglutide Market?

Leading companies in the liraglutide and semaglutide markets are developing anti-diabetic biosimilar drugs to enhance glucose control and reduce cardiovascular risks in diabetic patients. These anti-diabetic biosimilars are cost-effective, near-identical copies of original diabetes biologics, designed to deliver the same health benefits as the reference drugs. For example, in January 2024, Glenmark Pharmaceuticals Ltd., an India-based pharmaceutical company, introduced a biosimilar of the widely used anti-diabetic drug, Liraglutide, for the first time in India. This product is a biosimilar of Liraglutide, an anti-diabetic medication aimed at improving glycemic control among adults with type 2 diabetes mellitus. Its launch lowers daily therapy costs, significantly expanding access for more patients nationwide. Priced at approximately INR 100 for a standard 1.2 mg dose per day, this substantially reduces therapy costs by about 70% and requires a prescription for purchase.

Who Are The Core Companies Influencing Trends In The Liraglutide And Semaglutide Market?

Major companies operating in the liraglutide and semaglutide market are Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Merck & Co. Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Sanofi S.A., Novartis AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., Glenmark Pharmaceuticals Limited, Lupin Limited, Cipla Limited, Aurobindo Pharma Limited, Zydus Lifesciences Limited, Hikma Pharmaceuticals Plc, Viatris Inc., Amneal Pharmaceuticals Inc., Torrent Pharmaceuticals Limited, Intas Pharmaceuticals Limited

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/liraglutide-and-semaglutide-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Liraglutide And Semaglutide Market?

North America was the largest region in the liraglutide and semaglutide market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liraglutide and semaglutide market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Liraglutide And Semaglutide Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=18400&type=smp

Browse Through More Reports Similar to the Global Liraglutide And Semaglutide Market 2026, By The Business Research Company

Antiglaucoma Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/antiglaucoma-drugs-market

Semaglutides Market Report 2026

https://www.thebusinessresearchcompany.com/report/semaglutides-global-market-report

Liraglutide Market Report 2026

https://www.thebusinessresearchcompany.com/report/liraglutide-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795